Immix Biopharma Introduces Breakthrough NXC-201 for the Treatment of Relapsed/Refractory AL Amyloidosis
Immix Biopharma has introduced NXC-201 for the treatment of relapsed/refractory AL amyloidosis, a serious and progressive disorder.
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for NXC-201 based on interim Phase II data from the ongoing NEXICART-2 clinical trial. The study results were presented at the American Society of Hematology annual meeting in December 2025.
NXC-201 is a BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy designed to selectively target and eliminate abnormal plasma cells responsible for producing toxic light chains. In addition to Breakthrough Therapy Designation, NXC-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, as well as Orphan Drug Designation in the United States and the European Union.
AL amyloidosis is a rare disorder in which abnormal plasma cells produce misfolded light chain proteins that accumulate in organs such as the heart, kidneys and liver. This can lead to progressive organ damage and reduced survival. There are currently limited approved treatment options for patients whose disease has relapsed or become refractory.
NEXICART-2 is a multi-centre Phase II clinical trial being conducted in the United States to evaluate NXC-201 in patients with relapsed or refractory AL amyloidosis. The study has a registrational design and is expected to enrol approximately 40 patients.
NXC-201 is among the first investigational therapies to receive U.S. FDA Breakthrough Therapy Designation for the treatment of relapsed/refractory AL amyloidosis, providing a potential new treatment approach for patients living with this rare and serious disorder.
